Local treatment of antibacterial and analgesic of the affections limited to the mucosa, buccale and oropharynx.

NB: in the presence of general clinical signs of infection, bacterial, general antibiotic therapy should be considered.


1 spray 4 to 5 times a day

Child from 6 to 15 years old

1 spray 2 to 3 times a day


Preparation for oral or oropharyngeal use associating a local antiseptic of the family, biguanidines (chlorhexidine gluconate) and a local anesthetic (lidocaine hydrochloride).

- Do not use in children under 6 years

- Allergy known to local anesthetics and chlorhexidine

Possibility of false route by; anesthesia of the oropharyngeal intersection

- use this medicine with caution in children under 12 years

- do not use this medication before meals or before drinking

The indication does not warrant treatment, prolonged beyond 5 days as long as it could expose to an imbalance of the normal microbial flora of the oral cavity with a risk of bacterial or fungal spread. >

Repeated or prolonged treatment of the mucosa may expose to the risk of systemic toxic effects of contact anesthetics (central nervous system involvement with convulsions, depression, cardiovascular system). >

The attention of athletes will be drawn to the fact that this specialty contains an active ingredient (local anesthetic) which can induce a positive reaction of the tests performed during the antidoping tests. >

Special precautions for use

In case of persistence of symptoms beyond 5 days and / or associated fever, the course to be taken should be re-evaluated.

The simultaneous or successive use of other antiseptics is to be avoided in view of the possible interference (antagonism, inactivation ...)

Not applicable.

- Brown color of the tongue and teeth reversible upon cessation of treatment (chlorhexidine).

- Sensitization to chlorhexidine and local anesthetics with risk of anaphylactic reaction

- Passive numbness of the tongue, and possibility of false roads (see CAUTION)

Reporting of suspected adverse reactions

The reporting of suspected adverse effects after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and Network of Regional Centers of Pharmacovigilance; .ansm.sante.fr.

Local treatment of antibacterial and analgesic of the affections limited to the mucosa, buccal and oropharynx, NB: in front of the general clinical signs of infection, bacterial, antibiotic treatment by general way must be considered.